22 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists.
Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.
Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists.
Merck Sharp & Dohme Research Laboratories
A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.
Glaxosmithkline
Reactive derivatives for affinity labeling in the ifenprodil site of NMDA receptors.
University Of Strasburg
5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition.
Novartis Pharma
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
Astrazeneca Pharmaceuticals
Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.
Institut FüR Pharmazeutische Und Medizinische Chemie Der WestfäLischen Wilhelms-UniversitäT MüNster
Synthesis and biological evaluation of radio-iodinated benzimidazoles as SPECT imaging agents for NR2B subtype of NMDA receptor.
Hamamatsu University School Of Medicine
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
Friedrich-Schiller-Universitat Jena
Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists.
Merck Research Laboratories
Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.
Merck Research Laboratories
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
Merck Research Laboratories
Orally efficacious NR2B-selective NMDA receptor antagonists.
Merck Research Laboratories
3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.
Merck Research Laboratories
Parallel synthesis of a series of subtype-selective NMDA receptor antagonists.
Parke-Davis Pharmaceutical Research
Identification of novel chemical inhibitors for ubiquitin C-terminal hydrolase-L3 by virtual screening.
Waseda University
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
Bristol-Myers Squibb Pharmaceutical Research Institute